top of page

News of the Center

News — Summer 2023

diabetes, type 1 diabetes, type 2 diabetes, prediabetes, T1D, T2D, Diabetes mellitus, adult endocrinology, endocrinology, endocrinologist, University of Southern California, Keck Medicine of USC, Keck School of Medicine of the University of Southern California, USC, insulin pump, continuous glucose monitor, CGM, Peters on Diabetes, Anne Peters, Anne Peters MD, Dr Anne Peters, Anne L. Peters, Anne L. Peters MD, research, diabetes research, GLP-1, GLP1, GLP-1+GIP, GLP-1/glucagon, Ozempic, Wegovy, Mounjaro, Rybelsus, Intensive diabetes management, clinical trial, USC Westside Center for Diabetes, treatment of diabetes in adolescents and adults, adolescents, adults, diabetes education, nutritional counseling, lifestyle, Simple Language Guides, insulin pen, diabetes technology, SGLT2, Jardiance, Farxiga, Invokana, insulin, metformin, Freestyle Libre, Libre, Dexcom, Dexcom G7, Tandem, t:slim X2, Control-IQ, Omnipod, Omnipod 5, MiniMed 780G, Minimed, Medtronic, InPen, telemedicine, Beverly Hills, Los Angeles, California, diabetes doctor, diabetes physician, diabetes care, diabetes management, diabetes educator, CDCES, Diabetes Self Management Education and Support Program, DSMES, Castle Connolly Top Doctor, Top Doctor, America's Top Doctors, Internal Medicine, Diabetes and Metabolism, Endocrinologist & Diabetes Specialist, Diabetes Specialist, Dina Block MD, Beverly Hills Primary Care, USC Clinical Diabetes Program, Director of the USC Clinical Diabetes Programs, Professor of Medicine, Peters AL, Medscape

Message from the Director

September 2023


Dear Friends,


This era of incretin hormones, which started 15 years ago with Byetta, and has advanced through the variations Victoza, Saxenda and Bydureon. The field has recently exploded

into people’s consciousness over the past year in the form of Ozempic, Wegovy and Mounjaro. And at the ADA meeting this past June data on even more effective incretin hormones was discussed. For me the hype is tempered with a belief in the fact that lifestyle—diet and exercise—still and always will matter. All medications have side effects and people need to be aware of the risks. However, for those with type 2 diabetes the benefits of these agents far exceed the risks, especially for those who would otherwise be on insulin.


However, the incretin hormones are not the only key to a healthy life with diabetes. For many these medications are too expensive or have too many side effects. Other medications for treating diabetes still exist and can do a good job, although without the potential for weight loss. At the ADA meeting the 40-year anniversary of the landmark type 1 diabetes trial known as DCCT/EDIC showed the long-term value of early intensive glucose control to reduce the complications of high glucose levels. This follows the 44-year anniversary of the UKPDS trial which demonstrated similar benefits in people with type 2 diabetes.


The most exciting announcement at the meeting was a step in the direction of a treatment for type 1 diabetes using stem-cell derived beta-cells that has “cured,” or more precisely now made a handful of people who previously had type 1 diabetes insulin independent for over a year. This is possible due to the work of a company called Vertex which has developed a way to grow insulin-producing beta cells that have been implanted in six study participants and are working to various degrees in this small sample. Right now, all these individuals also need to take medications to also suppress their immune system from rejecting these new cells, but there is hope that there will be a way to eliminate this step in the future.


There are now a variety of automated insulin delivery system pumps that should soon start working with the new smaller continuous glucose monitors. The newest pumps are the Medtronic 780G, the Tandem Mobi and the easy-to-use Beta-Bionic iLet system. There are additional hybrid closed loop systems in development, but the limit to their effectiveness remains the relatively slow action of injected insulin.


More progress seems to be occurring in terms of treating and monitoring diabetes than ever before. Success is possible if access to diabetes care is available. And individualization of care is vital to diabetes management, which is what I strive to do for each of you.

L A T E S T   N E W S



This era of incretin hormones, which started 15 years ago with Byetta, and has advanced through the variations Victoza,




The breathless headlines about revolutionary injectable weight-loss drugs of Ozempic, Wegovy and Mounjaro and the oral version




Researchers, providers and especially people with type 1 diabetes have long wanted a cure for diabetes. Finally, there has been progress


Anne Medscape2-2023.jpg


Dr. Peters has a new collection of her news and opinion videos from her Peters on Diabetes series that include...,




A generous multi-year grant from the Hankey Foundation allowed us to expand the team’s work to treat patients with 


bottom of page